ReviewDiabetology & metabolic syndrome2026
Empagliflozin's role in cardiometabolic disease treatment: an Egyptian expert's view.
Review in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven the expanding therapeutic indications of empagliflozin (EMPA) beyond glycemic control and the growing burden of cardiometabolic diseases, this review evaluated its efficacy, safety, and cost-effectiveness in the Egyptian population within the global context.
methodsA comprehensive literature review of PubMed and Google Scholar identified clinical trials, systematic reviews, meta-analyses, and clinical guidelines published in English up to July 2025. We included studies reporting EMPA's pharmacological profile, mechanisms of action, and clinical outcomes on diabetes mellitus, cardiometabolic diseases, renal and hepatic functions, safety during Ramadan fasting, and cost-effectiveness.
resultsEMPA, as monotherapy or combination therapy, improves glycemic control in type 2 diabetes through Sodium-glucose co-transporter-2 (SGLT-2) inhibition. For type 1 diabetes mellitus, despite improving glycemic control as an adjunct therapy, it is not recommended due to the increased risk of diabetic ketoacidosis. EMPA reduces major cardiovascular events, heart failure hospitalization, and chronic kidney disease progression, with modest weight loss and blood pressure reduction, in patients with or without diabetes. Emerging evidence suggests benefits in metabolic dysfunction-associated steatotic liver disease (MASLD), although it is not approved for this indication. EMPA demonstrates a favorable safety profile and low hypoglycemia risk during Ramadan fasting. It enhances patients' quality of life and is considered cost-effective.
conclusionsEMPA extends beyond glucose-lowering by reducing cardiorenal morbidity and mortality in patients with or without diabetes. It shows a favorable safety profile, even during Ramadan fasting, supporting its suitability for the large Muslim population. Further research should evaluate its role in MASLD and assess cost-effectiveness in Egypt.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.